FundaMental Pharma
Key Facts
| Invested since | 2021 |
| Based in | Baden-Württemberg |
About the company
FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists succeeded in eliminating the toxic properties of the glutamate-controlled NMDA-type neurotransmitter receptor.
FMP has already identified first drug candidates that are currently in pre-clinical development and will be tested in humans within the next 2-3 years.
The discovery of an entirely new pharmacological principle (‘interface targeting’) raises hopes that previously untreatable neurodegenerative diseases in humans can be mitigated. Interface inhibitors open up new possibilities, both in terms of drug treatments and gene therapy approaches.
FMP was established in 2016 as a biotech start-up of the Interdisciplinary Center for Neurosciences (IZN) at Heidelberg University by Professor Hilmar Bading, Junior Professor Daniela Mauceri and Dr. Thomas Schulze.
Do you want to
know more about this company?
FundaMental Pharma in the news
Zum Artikel
Spacing rules in the brain: Novel compounds that act as molecular spacers in the brain prevent neurodegeneration
More startups from Life Sciences
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a …
ADVANOVA was founded in January 2012 by Dr. Frank Hemer, a doctor and computer scientist, and Bastian Bleisinger, a computer scientist. The company’s head office is in Erlangen at the …
ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.
Fiagon develops a new medical navigation system for intraoperative process control and positioning of instruments for ENT, head-/ neck- and neurosurgery.
MYR, acquired by Gilead Sciences in 2021, developed a peptide-based, first-in-class drug to combat chronic hepatitis B and delta. The drug has been approved by the EMA for the treatment …
PEPperPRINT produces customized ultra-high density peptide microarrays and uses individualized peptide libraries for drug development, antibody characterization, and protein biomarker discovery.
Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in …
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists …
TRIM TX is developing best-in-class Gamma-Secretase-Stabilizers (GSS) for the prevention and treatment of Alzheimer Disease.
SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A …
